Skip to main content
Top
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

MMTV-c-erbB-2 and MMTV-TGF alpha transgenic rats

Author: Michael Davies

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Many transgenic models of neoplastic disease have been produced in mice, including models of breast cancer. In comparison, few transgenic rat models have been described. Nevertheless, the rat remains an interesting model since the origin, pathology and sensitivity to hormones of rat mammary tumours closely resembles those of the human. Both TGF alpha and c-erbB-2 are commonly expressed, dominantly acting oncogenes in human breast cancer. TGF alpha is a member of the EGF family of proteins that induce a mitogenic response by activating members of the EGF tyrosine kinase receptor family, which includes c-erbB-2. However, results from transgenic mouse models using these genes, or their activated products, are somewhat ambiguous in several respects. …
Literature
1.
go back to reference Davies BR, Platt-Higgins AM, Schmidt G, Rudland PS: Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGF alpha transgenic rats. Am J Pathol. 1999, 155: 303-314.CrossRefPubMedPubMedCentral Davies BR, Platt-Higgins AM, Schmidt G, Rudland PS: Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGF alpha transgenic rats. Am J Pathol. 1999, 155: 303-314.CrossRefPubMedPubMedCentral
Metadata
Title
MMTV-c-erbB-2 and MMTV-TGF alpha transgenic rats
Author
Michael Davies
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66595

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine